Seeking Alpha

Synergy Pharmaceuticals posts a Q2 beat; announces spin-off of FV-100 assets

  • Synergy Pharmaceuticals (SGYP -0.2%) posts a solid Q2 beat as losses for the quarter were less than expected.
  • Cash and equivalents balance as of June 30 was $92.3M , up from $32.5M at the end of December, 2012.
  • Announces plans to spin off the part of its business working on a shingles treatment as a separate publicly traded company.
  • The newly formed subsidiary, ContraVir Pharmaceuticals, will hold the FV-100 assets in order to capitalize on significant growth opportunities and provide greater focus on the respective businesses and strategic priorities.
Comments (1)
  • Niksurfs
    , contributor
    Comments (89) | Send Message
    Does not get much better than this folks.... and the price is a steal
    9 Aug 2013, 02:48 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: